Press Releases | Y-mAbs Therapeutics, Inc.

Year

Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Q3 2023 DANYELZA® net product revenues of $20.0 million represents YoY growth of 59% U.S. FDA clearance of IND for CD38-SADA for relapsed or refractory non-Hodgkin Lymphoma Cash and cash equivalents of $86.6 million as of September 30, 2023 , with anticipated cash runway extended into 2027

Nov 13, 2023

Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023

NEW YORK , Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended September 30, 2023 , on Monday, November 13, 2023 , after the close of the U.S. financial markets.

Oct 31, 2023

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

NEW YORK , Oct. 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced today

Oct 18, 2023

Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA

Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company’s novel SADA technology platform NEW YORK , Oct. 17, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on

Oct 17, 2023

Y-mAbs Announces Publication in Cancers

Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment NEW YORK , Oct. 16, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company

Oct 16, 2023

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology

NEW YORK , Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Sep 21, 2023

Y-mAbs to Participate at Upcoming Investor Conferences in September

NEW YORK , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Sep 06, 2023

Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Q2 2023 DANYELZA® record net product revenues of $20.8 million , driving YoY growth of 112% and a 3% sequential increase compared to Q1 2023 Management reiterates FY 2023 financial guidance DANYELZA marketing authorization granted in Brazil Ongoing patient recruitment in the Phase I GD2-SADA

Aug 10, 2023

Y-mAbs to Participate at Upcoming Investor Conferences

NEW YORK , Aug. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Aug 02, 2023

Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023

NEW YORK , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the second quarter ended June 30, 2023 , on Thursday, August 10, 2023 , after the close of the U.S. financial markets.

Aug 01, 2023

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 22